The use of infliximab in South-east Asian children with severe Crohn's disease

W.S. LeeFollow

Document Type

Article

Publication Date

1-1-2004

Abstract

Childhood Crohn's disease (CD) has a chronic relapsing course with a high morbidity which includes delayed puberty, impaired growth, and perianal disease1. It is most prevalent in North America, North-west Europe, and in the United Kingdom, and is rare in Asia1. Many children with CD eventually need corticosteroid to control symptoms1. Tumor necrosis factor α (TNFα) is a proinflammatory cytokine which is important in the pathogenesis of CD2. Infliximab (Remicade, Schering-Plough, Kenilworth, New Jersey, USA), a chimeric anti-TNFα monoclonal antibody, induces remission in patients with moderately to severely active CD and can reduce corticosteroid requirements3. We share our experience in the use of infliximab in three South-east Asian children with severe CD.

Keywords

Crohn's disease, infliximab, perianal disease

Divisions

fac_med

Publication Title

Pediatrics International

Volume

46

Issue

2

This document is currently not available here.

Share

COinS